BMY News and Press, Bristol-Myers Squibb Company From 04/17/24

2024-04-17 09:30:00 ET Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long...

2024-04-16 12:22:50 ET More on rare disease pharmas/biotechs Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success...

2024-04-16 09:15:50 ET Summary PFE's dividend has reached the sky-high (for a biotech) ~6% mark. Are the dividend and recent share price decline enough to make PFE an attractive play? PFE is following a similar trajectory to GILD in its post-HCV stagnation. PFE may be wort...

2024-04-13 09:00:00 ET Summary The SWAN (Sleep Well At Night) strategy aims to achieve high-income, market-matching growth while minimizing volatility and draw-downs. The strategy consists of three buckets: Dividend Growth Investing, High Income (7 Funds), and Hedging (Rotational ...

2024-04-12 12:06:30 ET Summary Bristol Myers Squibb's share price continues to move sideways despite several regulatory approvals for its innovative drugs in the past six months. On April 2, 2024, the EMA approved Reblozyl as a first-line treatment for anemia in certain patients w...

2024-04-12 07:00:00 ET Summary Healthpeak Properties recently closed on its merger with Physicians Realty Trust, which is expected to generate merger-related synergies and be accretive to AFFO. The company reported strong earnings with solid growth in same-store NOI and AFFO. ...

2024-04-12 05:11:48 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

NORTHAMPTON, MA / ACCESSWIRE / April 11, 2024 / Bristol Myers Squibb Company: At Bristol Myers Squibb, our vision is to transform patients' lives through science Originally published on Bristol Myers Squibb News & Perspectives Since 1887, BMS has enabled positive change for patients...

2024-04-09 16:19:09 ET Bristol-Myers Squibb ( NYSE: BMY ) shares traded in the green on Tuesday, breaking a six-day losing spell. Stock closed up 0.98% at $51.60.... Read the full article on Seeking Alpha For further details see: Bristol-Myers Squibb snaps a six day ...

2024-04-09 05:49:33 ET Summary After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in th...